Serotonin-norepinephrine reuptake inhibitor

Milnacipran

Plain-language summaryIntrigue 60 / 100

Milnacipran, sold as Savella in the US (Ixel in Europe), is an SNRI primarily used for fibromyalgia. The European indication is depression. The (1S,2R)-enantiomer (levomilnacipran, Fetzima) is sold separately as a depression-focused agent. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

42/100

Approved SNRI with balanced SERT/NET profile, largely superseded by levomilnacipran for bench research

Milnacipran is a second-generation SNRI that has been on the market in France since 1997 and hit the US in 2009 as Savella, specifically for fibromyalgia. It operates the same fundamental way as venlafaxine and duloxetine – blocking serotonin and norepinephrine reuptake – but with a meaningfully different ratio. Most SNRIs are heavily SERT-biased; milnacipran sits at roughly 1:1 SERT/NET at therapeutic doses and tips toward NET preference at lower doses. Thats the whole pharmacological story here, and it’s a real if modest differentiator from the rest of its class.

Here’s the thing: that balanced profile was genuinely interesting when milnacipran first emerged, because the hypothesis that NET-biased SNRIs might address pain states differently than serotonin-dominant ones had real scientific logic. The fibromyalgia approval is direct evidence this logic played out, at least partially – FDA reviewers saw enough signal in the phase 3 data to greenlight it. The evidence base is solid. Multiple RCTs, decent N, regulatory approval in multiple jurisdictions. These aren’t things you dismiss.

What we don’t love is where milnacipran sits in the landscape right now. Levomilnacipran (Fetzima), the active (1S,2R) enantiomer, arrived in 2013 with even greater NET selectivity and largely superseded milnacipran as the compound of interest for investigators who care about the norepinephrine angle. If youre running a mechanistic study on NET inhibition ratios, you’re probably reaching for levomilnacipran or reboxetine before milnacipran. The parent compound doesn’t have a compelling edge over its own metabolite derivative, and that’s a real problem for differentiation scoring.

The fibromyalgia indication is the most distinctive thing about milnacipran from a research standpoint, and the central pain sensitization story is genuinely interesting biology. But the compound’s role there is more about demonstrating that central sensitization can be modulated pharmacologically than about milnacipran specifically being irreplaceable. Duloxetine covers overlapping ground with a larger evidence base and broader indication set. If your program is in central sensitization or fibromyalgia pathophysiology, milnacipran is a useful historical reference point but probably not your primary tool.

We see milnacipran as a mature approved pharmaceutical with well-characterized PK, a real if narrow clinical role, and limited headroom for novel research programs. It’s not junk – the fibromyalgia signal is real and the balanced monoamine profile remains a valid study tool for comparing SERT vs NET contributions across contexts. But for most bench programs in 2025, milnacipran has been superseded either by levomilnacipran for NET questions or duloxetine for fibromyalgia translational work with a larger literature behind it. The score reflects an approved, evidence-backed compound that has largely served its primary research purpose.

Novelty: 22
Mechanism promise: 38
In-category differentiation: 28
Evidence quality: 72
Translational signal: 68
Research bench value: 35

Rationale Milnacipran is a mature approved SNRI with genuine clinical utility in fibromyalgia, but its balanced SERT/NET profile is no longer novel and the active enantiomer levomilnacipran has largely superseded it for mechanistic research; evidence quality is high but novelty and differentiation are low, pulling the overall into the low-40s.

Serotonin-norepinephrine reuptake inhibitor

An SNRI marketed in Europe and Japan for depression and FDA-approved for fibromyalgia, with balanced SERT/NET inhibition.

Abstract

Milnacipran (Savella, Ixel; CAS 92623-85-3; molecular formula C15H22N2O; molecular weight 246.35) is a serotonin-norepinephrine reuptake inhibitor (SNRI) marketed in Europe, Japan, and Australia for major depressive disorder and FDA-approved in 2009 (Savella) for fibromyalgia. The compound has more balanced SERT and NET inhibition than venlafaxine or duloxetine (which are SERT-biased), with NET inhibition more prominent at lower doses. Approved doses are 100 mg per day in two divided administrations.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-192Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026

Venlafaxine

Plain-language summaryIntrigue 64 / 100

Venlafaxine (Effexor) was the first dual-action antidepressant, hitting both the serotonin and norepinephrine pumps in the same molecule. Wyeth got it approved in 1993. The catch is that the dual action depends on dose: at low doses it acts mostly like an SSRI; the norepinephrine effect only kicks in meaningfully above roughly 150 mg per day. The active leftover after the liver works on it does most of the heavy lifting at steady state, and that leftover is itself sold separately as desvenlafaxine. It has a notoriously brutal discontinuation profile because its half-life is short and patients feel every missed dose. Approved for depression, generalized anxiety, social anxiety, and panic disorder. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

40/100

The prototype SNRI; well-evidenced clinical drug with a settled mechanism and low bench-scale research novelty

Look, venlafaxine is the prototype SNRI. FDA approved in 1993, it was the first compound to demonstrate that adding noradrenergic reuptake inhibition on top of serotonergic blockade produced a meaningfully different clinical profile. That was actually interesting, in 1993. The dose-dependent transporter selectivity, predominantly serotonergic below 150 mg and genuinely dual-action above that threshold, gave pharmacologists a clean handle to study SERT/NET engagement ratios and established the template that duloxetine, milnacipran, levomilnacipran, and desvenlafaxine all followed.

The problem is thats 33 years of problem-solving. The mechanistic story is settled. The clinical evidence is massive and replicated across dozens of RCTs and meta-analyses covering depression, generalized anxiety, social anxiety, and neuropathic pain. The indication map is fully drawn. You can pull the venlafaxine pharmacology from a 2003 textbook and still be current in 2026. When a compound’s review papers lead with “as established in the original Wyeth trials”, thats not where you want to be as a bench investigator looking for signal.

We do credit it as a reference tool. If you’re building a dual-action antidepressant platform and need a positive control with clean pharmacokinetics and a well-characterized metabolic profile (CYP2D6 primary, CYP3A4 secondary, desvenlafaxine as the major active metabolite), venlafaxine is a reasonable anchor. The short parent half-life of approximately 5 hours, paired with the metabolite’s longer window of roughly 11 hours, also makes it a useful pharmacokinetic model for studying discontinuation biology and the temporal dynamics of dual-transporter withdrawal. Niche, but legitimate, and its why bench value isn’t zero here.

What we don’t like: the class is saturated and the alternatives are better on almost every research axis. Duloxetine has broader regulatory indications and cleaner tolerability data in comparative trials. Levomilnacipran has stronger NET selectivity if thats your target. Desvenlafaxine, the active metabolite, is now its own approved drug with its own literature. If you’re trying to probe SNRI pharmacology, you have more specific tools for nearly every question venlafaxine might answer, and most of them were designed to answer it better.

Honestly, the compound scores where it scores not because it’s ineffective; it’s a well-validated drug with a clear clinical footprint. It scores low because the research conversation has moved on. The mechanism is understood, the class is full, and the frontier questions in monoaminergic neuroscience, sigma-1 receptor involvement, neuroinflammatory crosstalk, predictive response biomarkers, are being answered with newer, purpose-built probes. Venlafaxine belongs in the reference library. It does not belong on the priority list.

Novelty: 12
Mechanism promise: 28
In-category differentiation: 22
Evidence quality: 78
Translational signal: 75
Research bench value: 45

Rationale Venlafaxine scores high on evidence and translational signal (approved drug, massive RCT base, replicated across indications) but near-rock-bottom on novelty and differentiation; the SNRI class is saturated, the mechanism is textbook, and newer alternatives answer almost every research question more cleanly. Overall 40 reflects a drug that works but offers no frontier for a serious bench investigator.

Serotonin-norepinephrine reuptake inhibitor

A bicyclic SNRI with dose-dependent transporter selectivity; the prototype dual-action antidepressant.

Abstract

Venlafaxine ((R/S)-1-[2-(dimethylamino)-1-(4-methoxyphenyl)ethyl]cyclohexan-1-ol; CAS 93413-69-5; molecular formula C17H27NO2; molecular weight 277.40) is a bicyclic phenethylamine SNRI developed at Wyeth and approved by the FDA in 1993 under the trade name Effexor. The compound is the prototype clinical SNRI, exhibiting dose-dependent transporter selectivity: at doses below 150 mg daily it functions as an SSRI (SERT inhibition predominates with NET inhibition becoming clinically meaningful only at higher doses); at 150 to 375 mg daily, NET engagement adds a noradrenergic component. The active metabolite O-desmethylvenlafaxine (desvenlafaxine, marketed separately as Pristiq) carries comparable transporter activity and contributes substantially to the steady-state effect. Plasma half-life of the parent compound is approximately 5 hours; the metabolite half-life is approximately 11 hours. Metabolism is via CYP2D6 (primary) and CYP3A4 (secondary). The compound exhibits a pronounced discontinuation syndrome, attributed to the short half-life and combined serotonergic-noradrenergic withdrawal. Used as the reference SNRI in mechanism studies and as a positive control in dual-action antidepressant pharmacology research.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-207Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026

Duloxetine

Plain-language summaryIntrigue 71 / 100

Duloxetine (Cymbalta) is an SNRI from Eli Lilly, approved in 2004, that hits the serotonin and norepinephrine pumps in roughly balanced fashion across its dose range (unlike venlafaxine, which only becomes a true SNRI at higher doses). The norepinephrine half of the action turns out to be useful for chronic pain, because pain-modulating circuits in the spinal cord rely on norepinephrine signaling. That is why duloxetine carries FDA approvals not just for depression and generalized anxiety but also for diabetic neuropathy, fibromyalgia, and chronic musculoskeletal pain, an unusually broad label for an antidepressant. Liver enzyme effects are notable, particularly through CYP1A2 and CYP2D6. Discontinuation is rough but generally less severe than venlafaxine. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

47/100

Mature approved SNRI with genuine pain indications but no meaningful research frontier left to explore

Look, duloxetine is a good drug. It does what it says. The dual SERT/NET inhibition is clean, the SERT/NET ratio of roughly 10 is genuinely more balanced than venlafaxine’s 30, and the regulatory approval across five distinct indications, including fibromyalgia and diabetic peripheral neuropathic pain, reflects a real pharmacological story about noradrenergic tone in descending pain modulation. We’re not dismissing it. We’re just being honest that 2004 was a long time ago and the mechanism has been worked to death.

The norepinephrine angle on pain is the most interesting thing here, and it remains the reason investigators reach for duloxetine as a reference compound when studying spinal descending inhibition. If you’re building a model of central sensitization or dorsal horn noradrenergic modulation, duloxetine is the logical positive control. Thats the bench value we credit, and it’s real. But it’s reference-standard bench value, not frontier probe value. You’re using it to anchor a system, not to ask a new question.

On the mechanism front, SNRI pharmacology is about as well-characterized as anything in psychopharmacology. CYP1A2 as primary metabolizer, moderate CYP2D6 inhibition producing real interactions with TCAs and tamoxifen, half-life around 12 hours. All of this is in every pharmacology textbook. We’re not finding anything new here. The dual-target story was genuinely exciting when Lilly was pushing it through FDA, but single receptor plus single receptor is not what we mean by multi-target pharmacology in 2026. Compare it to something like the dual GIP/GLP-1 biology in tirzepatide and you see how far the field has moved on what counts as interesting dual-target action.

The differentiation story is the strongest case for scoring this higher than a generic SSRI. Duloxetine occupies a real niche: it’s the approved-for-pain SNRI with the most balanced affinity profile, which gives it a genuine foothold in musculoskeletal and neuropathic pain research that compounds like escitalopram simply don’t have. It’s not one of many identical entries in its actual category, the pain-plus-mood space is thinner than it looks. But that unique angle doesn’t translate to research excitement because the mechanism explaining that unique angle is fully understood and the clinical effect is well-characterized.

Honestly, if you’re studying chronic pain biology, duloxetine earns a spot in your lab as a comparator. If you’re looking for the next thing in mood pharmacology or central sensitization, there is no reason to center a research program on it. The score reflects that. High evidence, high translation, low novelty, low mechanism excitement. That math produces a middle score, and a middle score is exactly right.

Novelty: 18
Mechanism promise: 28
In-category differentiation: 42
Evidence quality: 82
Translational signal: 78
Research bench value: 55

Rationale Duloxetine’s evidence quality and translational signal are genuinely high (it’s a multi-indication approved drug with solid phase 3 data), but those axes are the least-weighted in this rubric precisely because compelling evidence on a boring question isn’t what the library is for. Novelty is low, mechanism is well-trodden SNRI pharmacology, and the primary research value is as a reference standard for descending pain modulation work rather than as a frontier target.

Serotonin-norepinephrine reuptake inhibitor

A balanced-affinity SNRI distinguished by approval for chronic pain and diabetic peripheral neuropathy in addition to depression.

Abstract

Duloxetine ((S)-N-methyl-3-(naphthalen-1-yloxy)-3-(thiophen-2-yl)propan-1-amine; CAS 116539-59-4; molecular formula C18H19NOS; molecular weight 297.41) is a balanced-affinity SNRI developed at Eli Lilly and approved by the FDA in 2004 under the trade name Cymbalta. SERT (Ki approximately 0.8 nM) and NET (Ki approximately 7.5 nM) affinities are both nanomolar, with a SERT/NET ratio of roughly 10, more balanced than venlafaxine (ratio approximately 30). The compound exhibits weak DAT inhibition (Ki approximately 240 nM) of marginal clinical relevance. Plasma half-life is approximately 12 hours; metabolism is via CYP1A2 (primary) and CYP2D6 (secondary). The compound is itself a moderate CYP2D6 inhibitor, producing relevant interactions with TCAs, antipsychotics, and tamoxifen. Approved indications include major depressive disorder, generalized anxiety disorder, fibromyalgia, diabetic peripheral neuropathic pain, and chronic musculoskeletal pain. The pain indications reflect the noradrenergic component’s role in descending pain modulation. Used as the canonical balanced SNRI in mechanism studies and as a reference compound for descending pain modulation research.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-209Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026

Tag: Serotonin-norepinephrine reuptake inhibitor

Milnacipran

Abstract

Read the full monograph

Venlafaxine

Abstract

Read the full monograph

Duloxetine

Abstract

Read the full monograph